# Safety and Efficacy of Autologous Bone Marrow Mononuclear Cells in Patients With Severe Critical Limb Ischemia

> **NCT01472289** · PHASE1,PHASE2 · COMPLETED · sponsor: **TotipotentSC Scientific Product Pvt. Ltd.** · enrollment: 17 (actual)

## Conditions studied

- Critical Limb Ischemia

## Interventions

- **OTHER:** Autologous Bone Marrow Mononuclear cells (BMMNCs)

## Key facts

- **NCT ID:** NCT01472289
- **Lead sponsor:** TotipotentSC Scientific Product Pvt. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2013-01
- **Final completion:** 2013-07
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2015-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01472289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01472289, "Safety and Efficacy of Autologous Bone Marrow Mononuclear Cells in Patients With Severe Critical Limb Ischemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01472289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*